CMS: Open Payments Data Submission and Attestation Period Open until Midnight April 3, 2015 Read more
BioChemics, Inc. Pays the SEC $17.9 Million For Allegedly Misrepresenting FDA Review and Drug Trial Status To Investors Read more
District Court Denies Amgen’s Motion for Preliminary Injunction to Prevent Marketing of Sandoz’s Biosimilar Zarxio Read more
March 24 Webcast: “Beyond Product Launch: Navigating FDA Post-Market Requirements for mHealth and Health IT” Read more